Transgene Biotek Ltd
₹ 2.65
3.52%
15 Apr
- close price
About
Incorporated in 1990, Transgene Biotek Ltd
is in the business of Research & Development[1]
Key Points
- Market Cap ₹ 20.1 Cr.
- Current Price ₹ 2.65
- High / Low ₹ 5.26 / 1.83
- Stock P/E
- Book Value ₹ -1.10
- Dividend Yield 0.00 %
- ROCE -6.10 %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 23.6%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.97 | 0.30 | 0.18 | 0.28 | 0.12 | 0.07 | 0.00 | 0.17 | 0.09 | 0.06 | 0.23 | 0.26 | 0.23 | |
| 2.79 | 1.81 | 1.32 | 2.84 | 5.12 | 0.75 | 0.87 | 0.70 | 0.55 | 0.68 | 0.83 | 1.38 | 1.03 | |
| Operating Profit | -1.82 | -1.51 | -1.14 | -2.56 | -5.00 | -0.68 | -0.87 | -0.53 | -0.46 | -0.62 | -0.60 | -1.12 | -0.80 |
| OPM % | -187.63% | -503.33% | -633.33% | -914.29% | -4,166.67% | -971.43% | -311.76% | -511.11% | -1,033.33% | -260.87% | -430.77% | -347.83% | |
| -114.37 | 0.01 | 0.17 | 0.66 | 10.27 | 2.04 | 0.18 | 0.27 | 0.21 | 0.18 | 0.18 | 0.78 | 0.04 | |
| Interest | 0.00 | 0.36 | 0.07 | 0.43 | 1.03 | 0.26 | 0.38 | 0.27 | 0.23 | 0.62 | 0.14 | 0.24 | 0.97 |
| Depreciation | 17.22 | 17.18 | 20.50 | 17.53 | 9.89 | 9.89 | 9.90 | 9.91 | 9.92 | 4.95 | 0.09 | 0.09 | 0.17 |
| Profit before tax | -133.41 | -19.04 | -21.54 | -19.86 | -5.65 | -8.79 | -10.97 | -10.44 | -10.40 | -6.01 | -0.65 | -0.67 | -1.90 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 13.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| -133.40 | -19.04 | -21.54 | -19.86 | -6.44 | -8.79 | -10.96 | -10.43 | -10.40 | -6.01 | -0.66 | -0.68 | -1.90 | |
| EPS in Rs | -17.61 | -2.51 | -2.84 | -2.62 | -0.85 | -1.16 | -1.45 | -1.38 | -1.37 | -0.79 | -0.09 | -0.09 | -0.25 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | % |
| 3 Years: | 42% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 14% |
| 3 Years: | 25% |
| TTM: | -726% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -13% |
| 3 Years: | 1% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 |
| Reserves | 121.41 | 102.38 | 78.89 | -34.48 | -40.92 | -49.71 | -60.67 | -71.11 | -75.97 | -81.98 | -82.64 | -83.32 | -84.14 |
| 13.06 | 14.34 | 15.28 | 16.01 | 9.84 | 9.14 | 10.33 | 11.33 | 12.02 | 13.12 | 14.00 | 14.52 | 16.50 | |
| 139.21 | 137.84 | 123.15 | 30.88 | 31.97 | 31.45 | 31.43 | 31.01 | 25.40 | 25.57 | 25.31 | 27.23 | 25.73 | |
| Total Liabilities | 349.45 | 330.33 | 293.09 | 88.18 | 76.66 | 66.65 | 56.86 | 47.00 | 37.22 | 32.48 | 32.44 | 34.20 | 33.86 |
| 180.58 | 163.40 | 140.95 | 61.16 | 50.97 | 41.10 | 31.20 | 21.32 | 11.40 | 6.45 | 6.36 | 7.96 | 9.73 | |
| CWIP | 0.29 | 0.29 | 0.29 | 2.04 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 0.00 |
| Investments | 92.20 | 92.20 | 92.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.11 | 0.11 | 0.10 | 0.10 | 0.10 |
| 76.38 | 74.44 | 59.65 | 24.98 | 23.82 | 23.68 | 23.79 | 23.80 | 23.84 | 24.05 | 24.11 | 24.27 | 24.03 | |
| Total Assets | 349.45 | 330.33 | 293.09 | 88.18 | 76.66 | 66.65 | 56.86 | 47.00 | 37.22 | 32.48 | 32.44 | 34.20 | 33.86 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.11 | -0.95 | 0.02 | 0.02 | -0.63 | -1.74 | 0.14 | 0.01 | 0.10 | 0.00 | 0.00 | 1.20 | |
| 1.46 | -0.02 | -0.02 | 0.00 | 3.05 | 1.74 | 0.00 | -0.04 | -0.10 | -0.01 | 0.00 | -1.70 | |
| 0.60 | 0.94 | 0.00 | 0.00 | -2.37 | 0.00 | -0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.78 | |
| Net Cash Flow | -0.05 | -0.02 | 0.00 | 0.02 | 0.05 | 0.00 | -0.06 | -0.02 | 0.00 | -0.01 | 0.00 | 0.28 |
| Free Cash Flow | -2.11 | -0.95 | 0.02 | 0.02 | 2.74 | -0.01 | 0.14 | -0.02 | 0.10 | 0.00 | 0.00 | -0.50 |
| CFO/OP | 116% | 63% | -2% | -1% | 13% | 256% | -16% | -2% | -22% | 0% | 0% | -107% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 6,867.27 | 19,941.17 | 3,305.28 | 13.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventory Days | 106.46 | 365.00 | 365.00 | 1,460.00 | 121.67 | 156.43 | ||||||
| Days Payable | 25,975.83 | 5,018.75 | 3,528.33 | 13,870.00 | 1,460.00 | 1,199.29 | ||||||
| Cash Conversion Cycle | -19,002.11 | 19,941.17 | 3,305.28 | 13.04 | -4,653.75 | -3,163.33 | -1,338.33 | 0.00 | -1,042.86 | 0.00 | 0.00 | |
| Working Capital Days | -1,990.57 | -8,285.50 | -15,796.39 | -14,208.93 | -39,663.33 | -61,997.86 | -28,856.47 | -34,188.33 | -56,696.67 | -15,790.22 | -16,354.81 | |
| ROCE % | -6.58% | -9.27% | -11.85% | -17.10% | -14.75% | -25.79% | -34.93% | -49.11% | -73.14% | -57.55% | -7.26% | -6.10% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Intangible Assets - IP Rights and Technology Rupees in Lakhs |
|
||||||||||
| Intangible Assets Under Development Rupees in Lakhs |
|||||||||||
| Employee Benefit Expense Rupees |
|||||||||||
| Inventory (Raw Materials) Rupees in Lakhs |
|||||||||||
| R&D Expenditure (New/Annual) Absolute Value |
|||||||||||
| Equity Stake in NiedlFree Technologies Percentage |
|||||||||||
Requires Premium
Requires Premium
Documents
Announcements
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
2d - Transgene Biotek confirms it does not qualify as a Large Corporate under SEBI norms.
-
Intimation Of Non-Applicability Of Regulation 32(1) Of SEBI LODR) Regulations, 2015 For The Quarter Ended On 31St March 2026.
2d - Regulation 32 non-applicability intimated for quarter ended 31 March 2026; no public, rights or preferential issue.
-
Compliance-57 (5) : intimation after the end of quarter
2d - Reg. 57(5) not applicable for quarter ended 31 March 2026; no non-convertible securities issued.
-
Compliance-57 (4) : Prior intimation to the beginning of the quarter
2d - Regulation 57 not applicable as no non-convertible securities exist for Q4 FY2026.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 2d
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
TBL started as a Biotechnology company engaged in the manufacturing and selling diagnostic kits. The company expanded to biotech research, including the research and development of vaccines, oncology, New drug delivery technologies etc. Currently, the company has a product and technology portfolio covering Oncology, Oral Drug Delivery and Bio-generics.